Download PDF
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2023; 06(03): 104-117
DOI: 10.1055/s-0043-1764458
Review Article

Ramadan Fasting and Diabetes (2022): The Year in Review

Khadija Hafidh 
1   Department of Diabetes and Endocrinology, Rashid Hospital, DHA, Dubai, United Arab Emirates
2   Department of Medicine, Dubai Medical College, Dubai, United Arab Emirates
,
Tawfik A. Besheya
3   Department of Medicine, 11th June Clinic, Tripoli, Libya
4   Department of Clinical Skills, Faculty of Medicine, University of Tripoli, Tripoli, Libya
,
Rafik Elmehdawi 
5   Department of Medicine, Benghazi Medical Center, Benghazi, Libya
6   Department of Medicine, Faculty of Medicine, University of Benghazi, Benghazi, Libya
,
Salem A. Beshyah 
2   Department of Medicine, Dubai Medical College, Dubai, United Arab Emirates
7   Department of Medicine, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates
8   Department of Medicine, Yas Clinic Khalifa City, Abu Dhabi, United Arab Emirates
› Author Affiliations Funding and Sponsorship None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objectives The literature on the impact of Ramadan fasting (RF) on metabolic control and health in people with diabetes is widely spread in many journals making it not readily accessible to those interested in the subject. We aimed to provide a narrative overview of the global literature production in 1 year (2022) on diabetes and RF.

Materials and Methods It is a narrative, non-systematic review of the international literature from a single major medical online database (i.e., PubMed) in one calendar year (2022). Relevant literature was narrated in a concise thematic account.

Results Themes emerged from the review of the literature on RF published in 2022, including a couple of studies on the epidemiology of fasting in the real world by adults and children. Three studies involved some pathophysiological observations of metabolic and other biochemical markers. Several studies assessed the use and safety of different pharmacological therapeutic agents. Certain sulfonylureas, such as modified-release gliclazide, were considered safer than other sulfonylureas. Newer basal insulin analogs were studied in different geographical and socioeconomic settings (Gulf vs. South East Asia). The role of diabetes technology in Ramadan was the focus of several studies of insulin pumps and monitoring. Special themes were high-risk groups, pregnancy, acute complications, postbariatric surgery, and COVID-19 in Ramadan. Few studies examined the safety of sodium-glucose co-transporter-2 inhibitors as a class and individually during RF. Professional and patient perspectives released in 2022 included updated guidelines for adults and adolescents.

Conclusion In 2022's medical literature, RF and diabetes continue to address epidemiology, the burden of diabetes care on fasting patients, and discussions of concerns of patients and healthcare professionals. Risk stratification and issues of high-risk patients are still in focus for children, adolescents, and adults. Approaches to effective management still gather evidence for newer pharmacological agents and diabetes technology.

Keywords

Ramadan fasting - diabetes - hypoglycemia - epidemiology - diabetic ketoacidosis - patient perspectives - healthcare professionals

Compliance with Ethical Principles

No ethical approval is required. To the best of our abilities,we presented our perception of the published work in good faith. Original authors cannot be held responsible for any misrepresentation.


Authors' Contribution

S.A.B. proposed the study, performed the literature searches, and drafted the manuscript. All authors reviewed the whole document for intellectual content. All authors approved of its final version.




Publication History

Article published online:
03 April 2023

© 2023. Gulf Association of Endocrinology and Diabetes (GAED). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Beshyah WS, Beshyah SA. Bibliometric analysis of the literature on Ramadan fasting and diabetes in the past three decades (1989-2018). Diabetes Res Clin Pract 2019; 151: 313-322
    CrossrefPubMedGoogle Scholar
  • 2 Beshyah SA, Fathalla W, Saleh A. et al. Ramadan fasting and the medical patient: an overview for clinicians. Ibnosina J Med Biomed Sci. 2010; 2 (05) 240-257
    Article in Thieme ConnectGoogle Scholar
  • 3 Obaideen K, Abu Shihab KH, Madkour MI, Faris ME. Seven decades of Ramadan intermittent fasting research: bibliometrics analysis, global trends, and future directions. Diabetes Metab Syndr 2022; 16 (08) 102566 DOI: 10.1016/j.dsx.2022.102566.
    CrossrefPubMedGoogle Scholar
  • 4 Belheddad AZ, Azzoug S. Ramadan fasting in a sample Algerian population with diabetes. Diabetes Res Clin Pract 2022; 188: 109901 DOI: 10.1016/j.diabres.2022.109901.
    CrossrefPubMedGoogle Scholar
  • 5 Muammar T, Fojas EGF, Helal R, Lessan N. Ramadan fasting among older children and adolescents with type 1 diabetes mellitus: a real-world study from the UAE. Front Nutr 2022; 9: 786678 DOI: 10.3389/fnut.2022.786678.
    CrossrefPubMedGoogle Scholar
  • 6 Oueslati I, Kardi A, Boukhayatia F. et al. Impact of Ramadan intermittent fasting on metabolic and inflammatory profiles in type 2 diabetic patients. J Diabetes Metab Disord 2022; 21 (01) 751-758
    CrossrefPubMedGoogle Scholar
  • 7 Japar S, Fukunaga K, Kobayashi T. et al. A pilot study on the effect of D-allulose on postprandial glucose levels in patients with type 2 diabetes mellitus during Ramadan fasting. Diabetol Metab Syndr 2022; 14 (01) 86 DOI: 10.1186/s13098-022-00856-3.
    CrossrefPubMedGoogle Scholar
  • 8 Madkour MI, Hassan RE, Sherif NM. et al. Haptoglobin polymorphism modulates cardiometabolic impacts of four consecutive weeks, dawn to sunset Ramadan intermittent fasting among subjects with overweight/obesity. Diabetes Res Clin Pract 2022; 190: 110024 DOI: 10.1016/j.diabres.2022.110024.
    CrossrefPubMedGoogle Scholar
  • 9 Alharthi S, Alrajeh A, Alyusuf E, Alguwaihes AM, Jammah A, Al-Sofiani ME. “Pre-Ramadan” telemedicine: effect on fasting experience and glycemic control during Ramadan in people with type 1 diabetes. Diabetes Metab Syndr 2022; 16 (08) 102567 DOI: 10.1016/j.dsx.2022.102567.
    CrossrefPubMedGoogle Scholar
  • 10 Zainudin SB, Yeoh E. Preparing Muslims with diabetes mellitus for Ramadan fasting in Singapore: a clinical approach and review of current practice. Singapore Med J 2022; 63 (11) 633-640
    CrossrefPubMedGoogle Scholar
  • 11 Shiju R, Akhil A, Thankachan S, Tuomilehto J, Al Arouj M, Bennakhi A. Safety assessment of glucose-lowering drugs and importance of structured education during Ramadan: a systematic review and meta-analysis. J Diabetes Res 2022; 2022: 3846253 DOI: 10.1155/2022/3846253.
    CrossrefPubMedGoogle Scholar
  • 12 Soelistijo SA, Aman AM, Zufry H, Pranoto A, Rudijanto A, Hassanien M. Indonesia DIA-RAMADAN Study: a real-life, prospective and observational of gliclazide MR in type-2 diabetes patients during Ramadan fasting. Acta Med Indones 2022; 54 (01) 3-9
    PubMedGoogle Scholar
  • 13 Hassanein M, Sahay R, Hasan MI. et al. A real-world observational study of gla-300 in adults with type 2 diabetes who fast during Ramadan in the South Asia region: a subgroup analysis of the ORION study. Diabetes Ther 2022; 13 (04) 747-759
    CrossrefPubMedGoogle Scholar
  • 14 Malik RA, Elhadd T, Alattar A. et al. Safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan in the Gulf region: a subgroup analysis of the real-world ORION study. Diabetes Ther 2022; 13 (03) 569-581
    CrossrefPubMedGoogle Scholar
  • 15 Yousuf S, Ahmedani MY. Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting. Diabetes Metab Syndr 2022; 16 (11) 102633 DOI: 10.1016/j.dsx.2022.102633.
    CrossrefPubMedGoogle Scholar
  • 16 Sheikh A, Das B, Sattar S, Islam N. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population-an observational study from a tertiary care center in Karachi. Endocrine 2023; 80 (01) 64-70
    CrossrefPubMedGoogle Scholar
  • 17 Ahmed I, Raja UY, Wahab MU. et al. Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. BMC Endocr Disord 2022; 22 (01) 247 DOI: 10.1186/s12902-022-01168-3.
    CrossrefPubMedGoogle Scholar
  • 18 Goh KG, Zakaria MH, Raja Azwan RN, Bhajan Singh KK, Badrul Hisham MH, Hussein Z. Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia. Diabetes Metab Syndr 2022; 17 (01) 102680 DOI: 10.1016/j.dsx.2022.102680.
    CrossrefPubMedGoogle Scholar
  • 19 Pathan MDF, Akter N, Selim S. et al. Efficacy and safety of empagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: a real-world study from Bangladesh. Diabetes Metab Syndr Obes 2022; 15: 4011-4021
    CrossrefPubMedGoogle Scholar
  • 20 Gameil MA, Marzouk RE, El-Sebaie AH, Eldeeb AAA. Influence of sodium-glucose co-transporter 2 inhibitors on clinical and biochemical markers of dehydration during the Holy Ramadan. Diabetes Metab Syndr 2022; 16 (09) 102606 DOI: 10.1016/j.dsx.2022.102606.
    CrossrefPubMedGoogle Scholar
  • 21 Gad H, Al-Nassr N, Mohammed I. et al. Effect of Ramadan fasting in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors: a systematic review and meta-analysis. J Diabetes Investig 2022; 13 (05) 822-829
    CrossrefPubMedGoogle Scholar
  • 22 Kieu A, Iles A, Khan MA, Östlundh L, Boyd D, Faris ME. A systematic review of insulin management recommendations to improve glycemic control and reduce hypoglycemic events during Ramadan fasting in patients with insulin-requiring type 2 diabetes. Front Nutr 2022; 9: 846600 DOI: 10.3389/fnut.2022.846600.
    CrossrefPubMedGoogle Scholar
  • 23 Aldibbiat A, Alqashami A, Hussain S. Use of automated insulin delivery systems in people with type 1 diabetes fasting during Ramadan: an observational study. J Diabetes Investig 2022; 13 (04) 647-651
    CrossrefPubMedGoogle Scholar
  • 24 Algeffari M, Hussain S, Almogbel T, Alsharidah M, Alghadouni H, Mahmood F. Home use of mini-dose glucagon as a novel treatment for hypoglycemia following repeated, prolonged fasts in type 1 diabetes during Ramadan. Diabetes Care 2022; 45 (04) 990-993
    CrossrefPubMedGoogle Scholar
  • 25 Al Hayek AA, Robert AA, Al Dawish MA. Evaluating the impact of Ramadan fasting on ambulatory glucose profile among patients with type 1 diabetes using Flash Glucose Monitoring System: a comparative study. Diabetes Metab Syndr 2022; 16 (04) 102472 DOI: 10.1016/j.dsx.2022.102472.
    CrossrefPubMedGoogle Scholar
  • 26 Hasbullah FY, Mohd Yusof BN, Wan Zukiman WZHH. et al. Effects of structured Ramadan Nutrition Plan on glycemic control and variability using continuous glucose monitoring in individuals with type 2 diabetes: a pilot study. Diabetes Metab Syndr 2022; 16 (10) 102617 DOI: 10.1016/j.dsx.2022.102617.
    CrossrefPubMedGoogle Scholar
  • 27 Elbarbary NS, Ismail EAR. Glycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed–loop system: a randomized controlled trial. Diabetes Res Clin Pract 2022; 191: 110045 DOI: 10.1016/j.diabres.2022.110045.
    CrossrefPubMedGoogle Scholar
  • 28 Teoh ST, Hussain S, Hong JYH. Glycaemic changes among children and adolescents with type 1 diabetes mellitus before and during Ramadan fasting using continuous glucose monitoring. J ASEAN Fed Endocr Soc 2022; 37 (02) 49-59
    CrossrefPubMedGoogle Scholar
  • 29 Motaib I, Aitlahbib F, Fadil A. et al. Predicting poor glycemic control during Ramadan among non-fasting patients with diabetes using artificial intelligence based machine learning models. Diabetes Res Clin Pract 2022; 190: 109982 DOI: 10.1016/j.diabres.2022.109982.
    CrossrefPubMedGoogle Scholar
  • 30 Rahmatullah, Ahmedani MY, Basit A. et al. Evidence-based risk factors for major complications during Ramadan fasting in people with diabetes grouped under IDF-DAR risk categories. Diabetes Res Clin Pract 2022; 185: 109234
    CrossrefPubMedGoogle Scholar
  • 31 Baynouna AlKetbi L, Nagelkerke N, AlZarouni A. et al. Ramadan fasting outcome among high-risk patients. BMC Nephrol 2022; 23 (01) 304 DOI: 10.1186/s12882-022-02915-3.
    CrossrefPubMedGoogle Scholar
  • 32 Alshahrani M, Alraddadi A. Incidence of diabetic ketoacidosis during Ramadan compared with non-fasting months in King Saud Medical City, Riyadh, Saudi Arabia. J Family Med Prim Care 2022; 11 (07) 3905-3908
    CrossrefPubMedGoogle Scholar
  • 33 AlMogbel TA, Ross G, Wu T. et al. Ramadan and gestational diabetes: maternal and neonatal outcomes. Acta Diabetol 2022; 59 (01) 21-30
    CrossrefPubMedGoogle Scholar
  • 34 Ekhzaimy A, Alkatari S, AlMaatouq M. et al. Fructosamine as an index of short-term glycemic control in pregnant women with diabetes: before, during and after Ramadan. Int J Womens Health 2022; 14: 435-444
    CrossrefPubMedGoogle Scholar
  • 35 Ahmed M, Badi S, Elidrisi A. et al. Safety and effectiveness of newer antidiabetic medications during Ramadan fasting and safety of Ramadan fasting after bariatric surgery. J Diabetes Metab Disord 2022; 21 (02) 1991-2004
    CrossrefPubMedGoogle Scholar
  • 36 Helal R, Ashraf T, Majeed M, Lessan N. The effect of coronavirus disease-19 pandemic lockdown and the overlapping Ramadan fasting period on glucose control in insulin-treated patients with diabetes: a flash glucose monitoring study. Front Nutr 2022; 9: 843938 DOI: 10.3389/fnut.2022.843938.
    CrossrefPubMedGoogle Scholar
  • 37 Alamoudi RM, Aljohani NJ, Alfadhli EM. et al. Fasting Ramadan in patients with T1DM - Saudi Arabia versus other countries during the COVID-19 pandemic. Diabetes Metab Syndr 2022; 17 (01) 102676 DOI: 10.1016/j.dsx.2022.102676.
    CrossrefPubMedGoogle Scholar
  • 38 Zabeen B, Ahmed B, Nahar J. et al. Higher HbA1c was observed in young people with diabetes who fasted during COVID-19 pandemic lockdown of 2020 Ramadan in Bangladesh - a post Ramadan survey. Diabetes Res Clin Pract 2022; 186: 109812 DOI: 10.1016/j.diabres.2022.109812.
    CrossrefPubMedGoogle Scholar
  • 39 El Toony LF, Elghazally SA, Hamad DA. Positive impact of pre-Ramadan education on glycemic control and reducing risk of hypoglycemia in type 2 diabetic elderly patients during COVID 19 pandemic. Prim Care Diabetes 2022; 16 (04) 581-587
    CrossrefPubMedGoogle Scholar
  • 40 Sultana MS, Islam MS, Sayeed A. et al. Prevalence and correlates of diabetes distress and depressive symptoms among individuals with type-2 diabetes mellitus during Ramadan fasting: a cross-sectional study in Bangladesh amid the COVID-19. Diabetes Res Clin Pract 2022; 185: 109210 DOI: 10.1016/j.diabres.2022.109210.
    CrossrefPubMedGoogle Scholar
  • 41 Hassanein M, Afandi B, Yakoob Ahmedani M. et al. Diabetes and Ramadan: practical guidelines 2021. Diabetes Res Clin Pract 2022; 185: 109185 DOI: 10.1016/j.diabres.2021.109185.
    CrossrefPubMedGoogle Scholar
  • 42 Deeb A, Babiker A, Sedaghat S. et al. ISPAD Clinical Practice Consensus Guidelines 2022: Ramadan and other religious fasting by young people with diabetes. Pediatr Diabetes 2022; 23 (08) 1512-1528
    CrossrefPubMedGoogle Scholar
  • 43 Alabbood M, Alameri R, Alsaffar Y. Evaluation of physicians' approaches for the management of patients with diabetes during Ramadan in Iraq. Diabetes Res Clin Pract 2023; 195: 110188 DOI: 10.1016/j.diabres.2022.110188.
    CrossrefPubMedGoogle Scholar
  • 44 Al Rifai LA, Soubra L, Hassanein M, Amin MEK. Comprehensive care for patients with diabetes in Ramadan: a module for pharmacy students and pharmacists. Saudi Pharm J 2022; 30 (05) 619-628
    CrossrefPubMedGoogle Scholar
  • 45 Japar S, Ong SL, Muhamed Z. et al. Knowledge of diabetes and the practice of diabetes self-management during Ramadan fasting among patients with type 2 diabetes in Malaysia. Diabetes Metab Syndr 2022; 16 (11) 102655 DOI: 10.1016/j.dsx.2022.102655.
    CrossrefPubMedGoogle Scholar
  • 46 Bouchareb S, Chrifou R, Bourik Z. et al. “I am my own doctor”: a qualitative study of the perspectives and decision-making process of Muslims with diabetes on Ramadan fasting. PLoS One 2022; 17 (03) e0263088 DOI: 10.1371/journal.pone.0263088.
    CrossrefPubMedGoogle Scholar
  • 47 Akkuş Y, Kiliç SP. Feelings, difficulties and attitudes in relation to fasting: a qualitative study on spiritual coping among Turkish patients with type 2 diabetes. J Relig Health 2022; DOI: 10.1007/s10943-022-01713-3.
    CrossrefPubMedGoogle Scholar